文献速递银屑病与炎症性皮肤病

皮肤病与关节病中增强肝纤维化检测与P3NP的比较

Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP).
PubMed 文献 · Br J Dermatol · 2017-04-24

本研究纳入531例银屑病、银屑病关节炎和类风湿关节炎患者及对照,评估增强肝纤维化(ELF)检测的分布并与Ⅲ型前胶原氨基端肽(P3NP)比较。

要点

  • ELF评分和P3NP在银屑病、PsA和RA患者中均升高。
  • RA患者ELF>11和P3NP升高的比例最高。

核心结论

  • ELF评分和P3NP在银屑病、银屑病关节炎和类风湿关节炎患者中均升高。
  • ELF可能优于单独P3NP,但需进一步研究验证其预测肝纤维化的能力。

研究设计与样本

  • 横断面研究,共纳入531例患者,收集人口学、生活方式和疾病特异性数据,进行ELF和P3NP检测。

关键数值与推荐

  • ELF评分升高切点为>11。

临床怎么用

  • 在银屑病、PsA和RA患者中可考虑检测ELF评分以评估肝纤维化风险。
  • 中重度疾病患者应关注ELF评分升高,必要时进一步评估肝脏情况。

局限性

  • ELF检测在预测银屑病、PsA和RA患者肝纤维化易感性方面需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The enhanced liver fibrosis (ELF) test has been introduced to screen, diagnose and/or monitor liver conditions in large groups of patients with liver diseases. It has not been used in inflammatory skin or joint diseases. OBJECTIVES: To evaluate the distribution of the ELF test, apply existing cut-offs for hepatic patients and healthy controls, and compare it with the procollagen-3 N-terminal peptide (P3NP) test in patients with psoriasis (PSO), psoriatic arthritis (PsA) and rheumatoid arthritis (RA), and controls. METHODS: In total, 531 patients were included. Demographic, lifestyle and disease-specific data were collected. ELF and P3NP tests were performed. RESULTS: Prevalence of an increased ELF score (> 11) and P3NP was highest in patients with RA (7·7% and 6·1%, respectively) followed by patients with PSO (1·7% and 5·2%, respectively) and PsA (0·7% and 1·3%, respectively). Mean ± SD ELF scores for PSO, PsA and RA were, respectively, 9·09 ± 0·86, 8·96 ± 0·76 and 9·55 ± 1·04. All subgroups with moderate-to-severe disease severity had higher (> 9·8) ELF scores (PSO 27·0% vs. 18·3%; PsA 19·2% vs. 12%; RA 45·8% vs. 30·5%) and P3NP values. Distribution of the ELF score was smaller than the P3NP value [mean ± SD: 9·15 ± 0·92 (range 6·53-13·05) vs. 8·37 ± 4·30 (range 0·53-63·88)]. CONCLUSIONS: ELF score and P3NP are elevated in PSO, PsA and RA. ELF may be superior to P3NP alone, but further research should be done to validate the ELF test in determining susceptibility for developing liver fibrosis in PSO, PsA and RA.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. van der Voort EAM, Wakkee M, Veldt-Kok P, et al. Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). Br J Dermatol. 2017. PMID: 27925155. doi:10.1111/bjd.15220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。